Atlas Trials

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Clinical trial NCT03033524 · COMPLETED

Trial details

NCT number
NCT03033524
Sponsor
PharmAbcine
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2016-02-04
Primary completion
2017-06-02
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.